抗躁狂药物在急性躁狂症中的比较疗效和可接受性:多种治疗方法的元分析
Andrea Cipriani1, Corrado Barbui, Georgia Salanti
1Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Italy. andrea.cipriani@univr.it
Lancet (London, England)
|August 20, 2011
概括
里斯佩里,奥兰扎和哈洛皮多尔是急性躁狂的有效治疗方法,比安慰剂和其他一些药物更有效. 这些抗精神病药物可能是管理躁狂发作的首选选择.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 基于证据的医学是基于证据的医学.
背景情况:
- 传统的元分析显示,对于急性躁狂症的药理疗法,结果不一致.
- 通过直接和间接的比较,进行了多种治疗方法的元分析,以评估抗躁狂药物的疗效.
研究的目的:
- 为了比较各种药物治疗急性躁狂症的疗效.
- 根据全面的元分析,确定最有效的抗躁狂药物.
主要方法:
- 从1980年到2010年,对68项随机对照试验 (16,073名参与者) 的系统审查.
- 包括药物:阿里皮普拉,阿塞纳,卡巴马泽,瓦尔酸盐, gabapentin,哈洛佩里多尔,拉莫特里金,,奥兰扎,奎蒂亚,Risperidone,托皮拉和齐普拉西.
- 主要结果:躁狂评分尺度的变化和3周后患者退学率;治疗意图分析.
主要成果:
- 哈洛佩里多尔,瑞斯比里,奥兰扎,,奎提亚,阿里皮普拉,卡巴马泽,阿塞纳,瓦尔酸盐和齐普拉西比安慰剂更有效.
- 哈洛佩里多尔显示出最多的显著差异,并且比,奎平,阿里皮普拉,卡巴马西平,阿塞纳平,氨酸,齐普拉西,拉莫特里金,托皮拉玛酸和 gabapentin 更有效.
- 与,拉莫特里金,安慰剂,托皮拉和 gabapentin 相比,olanzapine,risperidone 和 quetiapine 的停药次数较少.
结论:
- 抗精神病药物在急性躁狂症中表现出比情绪稳定剂更大的有效性.
- 利斯佩里,奥兰扎和哈洛佩里多尔被推作为躁狂发作的主要治疗选择.
- 这些发现支持制定针对急性躁狂治疗的最新临床实践指南.
相关概念视频
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...